BioPharma Accord, Inc. reports the U.S. FDA has greenlit their application for a license regarding their proposed biosimilar to STELARA®, named DMB-3115.

Innate Pharma has been given the green light by the FDA to resume its Lacutamab Clinical Program after the previous partial clinical hold was removed.

Now the new regulation stresses that the old version of the test documents should be kept and indicated with expiration date.

Avenzo Therapeutics has disclosed the promising clinical phase CDK2 inhibitor known as AVZO-021, originally developed by Allorion Therapeutics.

Upon trial completion, the supervisor will retrieve the original case report form's first page, followed by data entry into the database for statistical analysis by the biostatistician per the pre-trial plan.

Inspirna teams up with German-based Merck KGaA to expedite the worldwide advancement of the drug Ompenaclid, known as RGX-202

TLR9 agonists are molecules that activate the Toll-like receptor 9, enhancing immune response against microbial infections.

Debiopharm is collaborating with Repare Therapeutics to investigate combining PKMYT1 and WEE1 inhibitors as a potential cancer treatment strategy.

According to the tenets of the declaration of Helsinki, subjects can withdraw from the trial at any time according to their own wishes without any reason.

D2 receptor antagonists are drugs that block the D2 subtype of dopamine receptors, used in treating conditions like schizophrenia and bipolar disorder.

KYV-101, a therapeutic agent by Kyverna, has been granted approval by the American FDA for use in a Phase 2 study, KYSA-7, targeting individuals suffering from advanced, treatment-resistant Multiple Sclerosis.

To safeguard participant privacy in the clinical trial, only initials—rather than full names—should be used in trial documents, particularly those submitted to the sponsor.